Breaking News

Catalent Expands Inhalation Capabilities

January 11, 2013

To invest $20 million in RTP site

Catalent Pharma Solutions is expanding its inhalation drug development, delivery and supply capabilities at its Inhalation Center of Excellence in Research Triangle Park (RTP), NC. The $20 million investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities.
 
Catalent provides a broad range of inhalation services including API optimization, pre-formulation, formulation, analytical testing and manufacturing across all inhaled dosage forms at the RTP facility.
 
“Pulmonary and nasal represents the second largest drug delivery market by delivery route. Catalent’s investment in commercial manufacturing at our Inhalation Center of Excellence not only fits with our advanced drug delivery growth strategy, but also positions us as a world leader supporting inhaled products,” said Scott Houlton, president of Catalent’s Development and Clinical Services business.
 
“In addition to the introduction of scalable processes for micro-dosing inhalation powder formulations, and the recent commissioning of our new nasal filling suite, this $20 million investment will upgrade our pMDI manufacturing capacity and allow us to better support our customers from early development all the way through to commercialization; bringing more products and better treatments to market faster,” Mr. Houlton added.
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer